On May 28, 2026 Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, reported that it has entered into a definitive agreement providing for the purchase and sale of an aggregate of 8,539,709 shares of its common stock at a purchase price of $0.5855 per share in a registered direct offering priced at-the-market under Nasdaq rules to GMS Ventures and Investments, the Company’s largest stockholder. The closing of the offering is expected to occur on or about May 29, 2026, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to the Company from the offering are expected to be $5.0 million, before deducting offering expenses payable by the Company. The Company intends to use the net proceeds from this offering, together with existing cash and cash equivalents, for working capital and general corporate purposes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The securities described above are being offered and sold by the Company in a registered direct offering pursuant to a "shelf" registration statement on Form S-3 (File No. 333-278340) that was originally filed with the Securities and Exchange Commission (the "SEC") on March 28, 2024, and that became effective on April 5, 2024. The offering of the securities in the registered direct offering is being made only by means of a base prospectus and prospectus supplement that forms a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus, when available, may also be obtained, when available, from the Company at 111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830, by phone at (609) 619-3990 or e-mail at [email protected].

The Company also has agreed to amend certain outstanding common stock warrants to purchase up to an aggregate of 15,488,570 shares of common stock previously issued to GMS Ventures and Investments in January 2025 and May 2025, with a weighted average exercise price of $1.78 per share, effective upon the closing of the offering, such that the amended warrants will have a reduced exercise price of $0.5855 per share.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

(Press release, Outlook Therapeutics, MAY 28, 2026, View Source [SID1234666151])

On May 28, 2026 HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, reported that it will be officially listed on the Taiwan Innovation Board on May 29, 2026, with an underwriting price of NT$120 per share.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HanchorBio is focused on developing differentiated immunotherapies targeting large unmet needs in oncology and autoimmune diseases. The Company’s core technology is its proprietary FBDB platform, which integrates multiple immune-modulating mechanisms into a single molecule and supports the development of multi-target, multifunctional biologic therapies.

Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio, said platform technology is an important foundation for building long-term biotechnology value. By supporting the generation of multiple research and development assets over time, platform capabilities may help diversify risks associated with single-asset drug development while strengthening the long-term potential of the Company’s pipeline.

HanchorBio has built a pipeline of clinical and preclinical candidates, including HCB101, HCB301, HCB303, and HCB206. The Company’s lead program, HCB101, is a CD47-targeting anti-cancer drug candidate designed through precision protein engineering to block tumor immune-evasion signals and restore macrophage-mediated tumor phagocytosis. HCB101 is currently being advanced in Phase 2a clinical development in combination with ramucirumab and paclitaxel for gastric cancer, while also being evaluated in additional indications, including head and neck cancer, colorectal cancer, and triple-negative breast cancer.

HCB301, a trifunctional fusion protein designed to address three key tumor immune-escape mechanisms, has entered Phase 1 clinical trials in the United States, mainland China, and Taiwan. HCB303 is a next-generation multi-target immunotherapy candidate currently under clinical development planning, while HCB206, the Company’s dual-mechanism autoimmune disease program, is viewed as an important potential driver of future pipeline value.

Dr. Liu noted that, in biotechnology licensing and partnership discussions, early clinical data supported by proof-of-concept findings are often a key factor in attracting global pharmaceutical partners. Such data may provide initial evidence of safety, clinical activity, and potential differentiation in patients.

HCB101 has shown encouraging early clinical activity in ongoing multinational Phase 1b/2a studies. In a mid-dose cohort evaluating HCB101 in combination with standard therapy for second-line gastric cancer, the regimen demonstrated an objective response rate (ORR) of 80%, with favorable safety and tumor reduction observations. Preliminary data from gastric cancer and first-line triple-negative breast cancer cohorts have also shown encouraging response and disease control signals. If subsequent Phase 2a proof-of-concept data across multiple indications remain supportive, the Company believes HCB101 may further positioned for global partnering discussions.

HanchorBio is pursuing a multi-indication clinical development strategy for HCB101, designed to support flexible business development opportunities, including licensing, co-development, and potential strategic transactions. Following its licensing agreement last year with Henlius for the development and commercialization rights to HCB101 in mainland China and certain territories, valued at up to US$202 million, HanchorBio has continued to advance discussions with multiple global pharmaceutical companies. The Company is currently engaged in ongoing partnering discussions for global and regional rights to HCB101 outside previously licensed territories.

(Press release, Hanchor Bio, MAY 28, 2026, View Source [SID1234666167])

On May 28, 2026 Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, reported that new clinical data from its legacy oncology asset ANV600 (sunekafusp alpha) will be presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following its strategic pivot to immunology, Anaveon is actively seeking global development and commercialization partners for its oncology portfolio to maximize the potential of these highly differentiated assets.

ANV600 is a first-in-class, non-blocking PD-1-targeted IL-2R-βγ agonist designed to selectively expand tumor-reactive PD-1+ CD8+ effector T cells while reducing the toxicities historically associated with IL-2 therapy. It is compatible with existing Check Point Inhibitors (CPI) and is positioned for use in CPI-resistant and CPI-relapsed patients.

Key results from the EXPAND-1 Phase 1 study will be highlighted in the poster:

The encouraging preliminary antitumor activity observed with ANV600 should be investigated further through additional clinical studies with larger patient populations,
ANV600 is well tolerated as a monotherapy and in combination with pembrolizumab,
A complete response (CR) was observed in a patient with NSCLC (non-small cell lung cancer) previously progressing on CPI and treated with ANV600 monotherapy at 120 µg/kg Q2W. Partial responses (PRs) were reported for two patients treated respectively with 30 µg/kg and 60 µg/kg ANV600 Q2W in combination with pembrolizumab Q3W,
Patients experienced target lesion shrinkage in 29% of patients receiving ANV600 monotherapy and 24% of patients receiving ANV600 plus pembrolizumab,
Disease control defined as Complete Response, Partial Response, or Stable Disease observed in 42% of patients treated with ANV600 monotherapy and 59% of the patients receiving ANV600 and Pembrolizumab,
Recommended Phase 2 dose of 90 µg/kg weekly for 4 weeks followed by 150 µg/kg Q2W established,
Patients Treatment with ANV600 resulted in higher absolute counts of CD8+ T cells and NK cells over regulatory T cells.
"Patients with advanced solid tumors treated with ANV600 derived meaningful clinical benefit, with approximately 24% of patients achieving a Complete Response, Partial Response or durable Stable Disease maintained for at least 18 weeks (≥3 tumor assessments)," said Prof. Dr. med. Markus Jörger of Health Ostschweiz (HOCH) in St. Gallen (Switzerland). "The trial provided a valuable treatment option for patients whose disease had progressed beyond available therapies. ANV600 demonstrated a promising safety-efficacy profile, together with compelling proof-of-mechanism in patients with advanced solid tumors."

ASCO Annual Meeting abstracts may be accessed online via View Source

Presentation Details:
Title: Safety, PK/PD, and efficacy results from Expand-1: A phase 1 dose escalation study of the novel PD-1 targeted IL-2R-βγ agonist sunekafusp alpha (ANV600) as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Markus Joerger
Abstract number: 2587
Session Title: Development Therapeutics- Immunotherapy
Poster board: 377
Location, Date and Time: Hall A, May 30, 2026, 1:30 to 4:30 pm, CDT

"With established clinical benefits and strong interest from current clinical investigators, we believe that ANV600 is ideally suited for a partner with the resources and expertise to bring it forward in CPI-resistant NSCLC and other immuno-oncology indications," added Thaminda Ramanayake, Chief Executive Officer of Anaveon.

Anaveon’s proprietary oncology product portfolio is built around a non-blocking PD-1 targeted cytokine platform. This highly selective "cis-signaling" proximity-activated delivery of cytokines is precise and combinable with Check Point Inhibitors. In addition to ANV600, the platform includes ANV700, a preclinical proximity-activated PD-1-targeted IL-21 fusion protein with potential for synergistic effects when combined with IL-2-based approaches and another undisclosed preclinical program. Included in the oncology portfolio is ANV419, an earlier generation (non-PD-1-targeted) IL-2/anti-IL-2 fusion protein with demonstrated safety in prior clinical studies.

The company is now prioritizing its core immunology pipeline and is open to various partnering structures (license, co-development, or acquisition) for the oncology platform and portfolio.

(Press release, Anaveon, MAY 28, 2026, View Source [SID1234666183])

On May 28, 2026 Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada" or the "Company"), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, reported that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference Details
Format: Fireside Chat
Date: Thursday, June 4, 2026
Time: 12:50 PM ET
Webcast: Click Here

Management will also be available for one-on-one investor meetings during the conference. Please contact your Jefferies representative to schedule a meeting.

The webcast can also be accessed on the Events page of the Investors section of the Relmada website at View Source An archived replay will be available for 90 days following the conclusion of the event.

(Press release, Relmada Therapeutics, MAY 28, 2026, View Source [SID1234666152])

On May 28, 2026 BostonGene, developer of the leading AI model for tumor and immune biology, reported that nine abstracts have been accepted at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting (ASCO) (Free ASCO Whitepaper), scheduled to take place May 30 – June 2, 2026, at McCormick Place Convention Center in Chicago, IL. BostonGene will also exhibit at booth #33137.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstracts underscore the broad clinical utility of BostonGene’s AI-powered models and advanced analytical platforms, including the Tumor Portrait test and Kassandra cell deconvolution. Spanning both tissue and peripheral blood analysis, the featured research showcases how integrating deep genomic, transcriptomic, and immunomic profiling can identify novel actionable biomarkers, predict immunotherapy response and toxicity, and map complex resistance mechanisms. Developed in collaboration with leading institutions such as the UT MD Anderson Cancer Center, Weill Cornell Medicine, and the Parker Institute for Cancer Immunotherapy, these studies highlight BostonGene’s pivotal role in accelerating biomarker discovery and optimizing patient stratification for clinical trials.

Details about the abstracts selected for presentation can be found below:

Poster presentations
Poster number: 273
Title: TROP2 as an actionable biomarker for anal cancer
Date & time: May 30 | 9:00 AM – 12:00 PM
Speaker: Mir Lim, MD, UT MD Anderson

BostonGene and MD Anderson Cancer Center collaborated to perform comprehensive genomic profiling of localized and metastatic anal cancers, assessing TACSTD2 (TROP2) expression as a potential therapeutic biomarker. The analysis found high TACSTD2 expression that correlated with TROP2 immunohistochemistry, supporting its potential use in identifying patients who may benefit from anti-TROP2 antibody-drug conjugates. The study underscores the clinical utility of BostonGene’s Tumor Portrait test in biomarker discovery and validation.

Research conducted in collaboration with UT MD Anderson

Poster number: 257
Title: Developing harmonized tumor microenvironment subtypes for patient stratification in clinical trials
Date & time: May 30 | 1:30 PM – 4:30 PM
Speaker: Sofya Kust, PhD, BostonGene

BostonGene developed an AI-driven harmonized tumor microenvironment (HTME) classification system to improve patient stratification for immunotherapy and targeted therapies across solid tumors. By applying machine learning approaches—including agglomerative clustering, K-nearest neighbors classification, and transcriptomic pathway analysis—to RNA-seq data from more than 40,000 cancer samples, the study identified nine reproducible TME subtypes capturing key biological features such as immune activity, fibrosis, vascularization, and hypoxia. The AI-based framework outperformed existing methods by integrating multiple biological dimensions simultaneously and accurately predicting treatment response and progression-free survival across different cancer types and therapies.

Poster number: 323
Title: Multimodal immunoprofiling of peripheral blood using foundation models of the immune system for predicting immunotherapy response and toxicity in the RADIOHEAD pan-cancer cohort
Date & time: May 30 | 1:30 PM – 4:30 PM
Speaker: Evgeny Barykin, PhD, BostonGene

In collaboration with Parker Institute for Cancer Immunotherapy, BostonGene applied AI-based models of the immune system to analyze blood samples from more than 1,000 cancer patients receiving immune checkpoint inhibitor (ICI) therapy in the RADIOHEAD pan-cancer cohort. By combining RNA sequencing, flow cytometry, and machine learning models trained on 45,000 patient profiles, the study identified immune signatures linked to both treatment response and severe immune-related toxicities. The AI-driven embeddings and multimodal immunoprofiling approach successfully stratified patients into responder, non-responder, and high-risk toxicity groups, highlighting the potential of AI-powered peripheral blood profiling to improve immunotherapy patient selection.

Research conducted in collaboration with Parker Institute for Cancer Immunotherapy

Poster number: 360
Title: Effects of a multimodal TCR/BCR repertoire foundation model on blood RNA-seq–based prediction of severe adverse event risk and rheumatoid arthritis
Date & time: May 30 | 1:30 PM – 4:30 PM
Speaker: Alexander Bagaev, PhD, BostonGene

BostonGene utilized its immune model leveraging multimodal TCR/BCR repertoire data to address two critical clinical challenges: predicting severe immune-related adverse events (irAEs) in cancer patients receiving immune checkpoint inhibitors and detecting rheumatoid arthritis from peripheral blood. By integrating adaptive immune receptor repertoire embeddings with gene expression signatures, the model significantly outperformed traditional immune repertoire analysis approaches—such as clonality, diversity, and V(D)J gene usage metrics—in both predictive accuracy and cross-cohort robustness. These advances enabled earlier risk stratification and more precise immunotherapy management than conventional biomarker methods.

Poster number: 533
Title: Immune priming with the EZH2 inhibitor tazemetostat in B-cell lymphomas receiving CART cell therapy
Date & time: June 1 | 9:00 AM – 12:00 PM
Speaker: Samuel Yamshon, MD, Weill Cornell Medicine

BostonGene applied its multimodal molecular profiling platform to characterize the systemic immune remodeling driven by tazemetostat priming in patients with B-cell lymphomas receiving CART therapy. By integrating high-parameter flow cytometry, RNA sequencing, immune cell deconvolution, and functional gene signature analysis, BostonGene’s analysis revealed systemic immune remodeling associated with enhanced antigen presentation, T-cell activation, and reduced immunosuppressive signaling—supporting the use of EZH2 inhibition for improved CART efficacy and durability.

Research conducted in collaboration with Weill Cornell Medicine

Poster number: 268b
Title: IvoLoC: A phase II trial of ivonescimab (IVO) in endocrine-refractory hormone receptor (HR)-positive or triple-negative (TN) metastatic invasive lobular carcinoma (mILC)
Date & time: June 1 | 1:30 PM – 4:30 PM
Speaker: Jason Mouabbi, MD, UT MD Anderson

In a trial in progress with UT MD Anderson Cancer Center, BostonGene will perform multimodal longitudinal blood and tissue analysis for mILC patients receiving the bispecific antibody targeting PD-1 and VEGF, ivonescimab. Moving beyond traditional efficacy metrics, complex correlates linking clinical outcomes with molecular features are ongoing. By integrating real-time ctDNA dynamics with predictive responder scores, BostonGene aims to identify critical markers of response and resistance needed to optimize treatment durability and refine future trial strategies.

Research conducted in collaboration with UT MD Anderson

Online only
Abstract number: e12594
Title: Examining the tumor microbiology and microenvironment of patients with triple negative inflammatory breast cancer receiving Keynote 522

Stage III triple‑negative inflammatory breast cancer patients receiving KN522 therapy were analyzed with BostonGene’s integrative multimodal platform. By combining intrinsic subtype classification with immune deconvolution, BostonGene successfully mapped the molecular landscape of treatment response. Non-responders were marked by angiogenic and endothelial remodeling and potential biomarkers of brain metastasis risk, demonstrating the platform’s unique capability to predict both therapeutic outcomes and disease progression.

Research conducted in collaboration with UT MD Anderson

Abstract number: e13080
Title: Real-world clinical utility of comprehensive genomic and transcriptomic profiling in metastatic breast cancer (mBC)
Description: Clinicians at MD Anderson Cancer Center utilized BostonGene’s Tumor Portrait test to validate the impact of comprehensive genomic profiling in guiding treatment decisions and predicting outcomes in a heterogeneous real-world mBC cohort. The findings demonstrated that BostonGene’s integrated approach uncovered clinically actionable insights and predictive signatures that directly guided treatment selection and improved patient outcomes.

Research conducted in collaboration with UT MD Anderson

Abstract number: e16004
Title: Association of angiogenic, fibrotic, and immunosuppressive tumor microenvironment with immunotherapy outcomes in metabolic disease–associated biliary tract cancers

Researchers at MD Anderson Cancer Center leveraged BostonGene’s transcriptomic classifiers and KassandraTM cell deconvolution to characterize the tumor microenvironment (TME) of metabolic disease-associated biliary tract cancers. The analysis uncovered a distinct TME in metabolic disease-associated cholangiocarcinoma that likely impairs response to immune checkpoint inhibitors, demonstrating the value of BostonGene’s AI-powered solutions for therapeutic response prediction and trial design.

Research conducted in collaboration with UT MD Anderson

For more information, please visit the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting website. The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO (Free ASCO Whitepaper) Annual Meeting Proceedings.

(Press release, BostonGene, MAY 28, 2026, View Source [SID1234666168])